KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel

The KRAS-variant is a germline single nucleotide polymorphism (SNP) within the 3'UTR of the KRAS gene predicted to disrupt a complementary binding site (LCS6) for the let-7 microRNA (miRNA). The KRAS-variant is associated with increased risk of various cancers, including lung cancer, ovarian ca...

Full description

Saved in:
Bibliographic Details
Published in:Cell cycle (Georgetown, Tex.) Tex.), 2012-01, Vol.11 (2), p.361-366
Main Authors: Kundu, Samrat T, Nallur, Sunitha, Paranjape, Trupti, Boeke, Marta, Weidhaas, Joanne B, Slack, Frank J
Format: Article
Language:English
Subjects:
3' Untranslated Regions
Alleles
Binding Sites - genetics
Cell Line, Tumor
Epigenesis, Genetic
Gene Expression
Gene Expression Regulation, Neoplastic
Humans
MicroRNAs - metabolism
Mutation
Open Reading Frames
Polymorphism, Single Nucleotide
Proto-Oncogene Proteins - genetics
Proto-Oncogene Proteins p21(ras)
ras Proteins - genetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The KRAS-variant is a germline single nucleotide polymorphism (SNP) within the 3'UTR of the KRAS gene predicted to disrupt a complementary binding site (LCS6) for the let-7 microRNA (miRNA). The KRAS-variant is associated with increased risk of various cancers, including lung cancer, ovarian cancer and triple-negative breast cancer, and is associated with altered tumor biology in head and neck cancer, colon cancer and melanoma. To better understand the molecular pathways that may be regulated or affected by the presence of the KRAS-variant allele in cancer cells, we examined its prevalence in the NCI-60 panel of cell lines and sought to identify common features of the cell lines that carry the variant allele. This study provides a step forward towards understanding the molecular and pathological significance of the KRAS-variant.
ISSN:1551-4005
DOI:10.4161/cc.11.2.18794